Courtesy of the SBHCI. Chronic stable angina and severe coronary lesion patients who undergo angioplasty in a single vessel show no better outcomes than individuals who undergo a placebo sham procedure when it comes to exercise capacity and symptoms, according to this study presented at TCT and published simultaneously in the Lancet. The curious results<a href="https://solaci.org/en/2017/11/06/tct-2017-orbita-the-placebo-effect-of-angioplasty/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Coronary perforation (CP) is a very uncommon event (≈0.4%), associated with severe complications that entail risk of death. It has usually been related to patients with a history of myocardial revascularization surgery (MRS). However, this group usually presents lower rates of cardiac tamponade due to pericardial fibrosis caused by surgery. This<a href="https://solaci.org/en/2017/10/05/frequency-and-evolution-of-cardiac-perforation-in-patients-with-a-history-of-mrs/" title="Read more" >...</a>
Fractional flow reserve (FFR) has proven to be superior to angiography as a guide to revascularization due to a significant reduction in the number of both long-term and short-term events. Furthermore, deferring treatment of lesions without evidence of ischemia offers an excellent prognosis. Many studies including mostly stable patients showed a significant degree (as high<a href="https://solaci.org/en/2017/09/12/routine-ffr-in-patients-with-acute-coronary-syndrome/" title="Read more" >...</a>
The first and only randomized trial on chronic total occlusion (CTO) revascularization versus optimal medical therapy in stable patients has disappointed interventional cardiologists. According to Dr. Seung-Jung Park, who presented the study, evidence suggests that optimal medical therapy is a reasonable initial treatment strategy for chronic total occlusion, when compared with angioplasty. Critics<a href="https://solaci.org/en/2017/04/08/decision-cto-prevailing-questions-on-cto-rechanneling/" title="Read more" >...</a>
Deferring treatment through angioplasty in non-ischemic lesions by fractional flow reserve (FFR) is associated with excellent long-term prognosis in patients with chronic ischemic heart disease. FFR is beginning to be used for clinical decision-making in patients with acute coronary syndromes, and its long-term effect on stable chronic patients has not been established. This<a href="https://solaci.org/en/2016/09/21/deferring-lesions-by-ffr-in-acs-yes-or-no/" title="Read more" >...</a>
This study examines predictors and outcomes associated with the prescription of beta-blockers at discharge after a successful coronary angioplasty in patients with stable chronic angina WITHOUT prior history of acute myocardial infarction or heart failure. The benefit of beta-blockers in patients with acute myocardial infarction or systolic heart failure is well documented. However, their<a href="https://solaci.org/en/2016/08/23/beta-blockers-for-revascularized-patients-to-prescribe-or-not/" title="Read more" >...</a>
Original Title: Impact of routine Fractional Flow Reserve on management decision and 1-year clinical outcome of ACS patients: Insights from the POST-IT and R3F Integrated Multicenter registriEs –Implementation of FFR in Routine Practice (PRIME-FFR). Presenter: Luís Raposo. Supported by a large body of evidence, the use of fractional flow reserve (FFR) has clearly been<a href="https://solaci.org/en/2016/05/23/prime-ffr-safe-in-acute-coronary-syndrome/" title="Read more" >...</a>
The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were randomized diagnosed with type 2 diabetes with a history of cardiovascular events or high risk to receive saxagliptin or placebo. Other medications for diabetes, including hypoglycemic, were permitted. The combined<a href="https://solaci.org/en/2015/06/24/savor-timi-53-saxagliptin-showed-no-cardiovascular-benefit/" title="Read more" >...</a>
Original title: Relation of C-reactive protein levels to instability of untreated vulnerable coronary plaques (from the PROSPECT study). Reference: Kelly CR et al. Am J Cardiol. 2014;Epub ahead of print. The original PROSPECT study included 697 patients with acute coronary syndrome (ACS) undergoing culprit artery percutaneous coronary intervention (PCI) followed by intravascular ultrasound (IVUS) to the rest of<a href="https://solaci.org/en/2014/06/09/elevated-c-reactive-protein-levels-could-predict-future-events-associated-to-non-culprit-lesions-prospect-study-sub-analysis/" title="Read more" >...</a>
Original title: Dedicated two-stents technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: The EES-bifurction study. Reference: Nisharamed I. Kherada, et al. International Journal of Cardiology 2014;174:13-17 Bifurcation PCI, especially 1.1.1 Medina bifurcation lesions PCI, is particularly challenging and has been associated with increased restenosis. The use of drug eluting stents (DES) associated to<a href="https://solaci.org/en/2014/05/27/dedicated-two-everolimus-eluting-stent-strategies-improve-bifurcation-pci-outcomes/" title="Read more" >...</a>